• About
  • Contact
  • Editorial
  • Policies
  • Archives
Angry Bear
Relevant and even prescient commentary on news, politics and the economy.
  • US/Global Economics
  • Taxes/regulation
  • Healthcare
  • Law
  • Politics
  • Climate Change
  • Social Security
  • Hot Topics
« Back

Open thread March 8, 2016

Dan Crawford | March 8, 2016 6:51 am

Tags: open thread Comments (4) | Digg Facebook Twitter |
4 Comments
  • William Ryan says:
    March 9, 2016 at 3:21 pm

    At first many were saying Trump couldn’t, he did. Now they are saying old Bernie can’t, he will…So it will come down to Trump vs. Sanders and I will be happy either way. It will be a win-win situation for America to become great again..

  • Denis Drew says:
    March 9, 2016 at 5:37 pm

    ” Less than a year ago, Pearson’s cheerleaders—many of them professional money managers, such as Bill Ackman of Pershing Square Capital Management—were saying that he was revolutionizing the pharmaceutical industry. Pearson had long argued that the industry wasted too much money on unprofitable research and development projects. He said drugmakers were better off buying other companies and exploiting their portfolios. Accordingly, he had turned Valeant into an acquisition machine and, though he rarely discussed it, a serial hiker of drug prices, another pillar of the company’s strategy. ” (my emphasis)

    ” Other pharmaceutical companies learned from Pearson’s model, too. Pfizer, the maker of drugs such as Viagra, was essentially going down a path blazed by Valeant when it announced it would buy Allergan in a $160 billion deal that would be the largest in the industry and that would transform (or “invert”) it into an Irish-domiciled company, enabling it to avoid American corporate taxes. ”

    Read all about it here:
    http://www.bloomberg.com/news/articles/2016-03-03/valeant-s-boss-is-back-can-the-ceo-save-the-day-again
    * * * * * *
    ” … but my experience in med-tech tells me that there is almost always a way around IP and that good ideas (or what companies think will be good ideas) are copied pretty quickly – notice how many companies got into renal nerve ablation once that seemed promising or how many companies have launched clinical programs in transcatheter heart valves. ”
    http://seekingalpha.com/article/3934666-can-sunshine-heart-survive-see-dawn?auth_param=17tckm:1bd3k0r:1333c28776918ba740d9bea4d932addc&dr=1

    Novel, implantable device ‘could slow, reverse heart failure’
    Read all about first ever device to successfully treat or even for the first time ever even cure some patients with heart failure — with on add risk of stroke or clots because it is outside the bloodstream. Too bad under US research culture or whatever you call it it may lie neglected because investors are afraid it is too easy to copy.
    http://www.medicalnewstoday.com/articles/283566.php
    * * * * * *
    We all know the story of Sovaldi where the company paid $11 billion to a company who was going to sell the $1-to-make pills for $350 so they could sell it for $1000 a pill. Cure for Hepatitis C permanently put on hold so Wall Street can gouge. The first company relied on government research funds until it smelled money than it was able to find investors to finish the job. The chief scientist made $446 million for himself — enough to manufacture the virus out of business.

    We’ll never do anything about any of this — or anything else — if we don’t return to the union density of the 50s and 60s.

    • run75441 says:
      March 9, 2016 at 8:53 pm

      True on Pfizer

  • Denis Drew says:
    March 9, 2016 at 5:54 pm

    Tacking this on to the above – couldn’t find it at first:

    HF (Heart Failure) is a terrible disease , but unfortunately is very common. It is currently poorly treated, and is one of few diseases that increase in mortality YoY. More than 7 million HF patients exist in the US, with more than 800,000 new HF cases every year. The number of HF patients is expected to exceed 10 million by 2030. The HF increase in prevalence is driven by the epidemics of obesity, diabetes, and high blood pressure. Additionally, 7-10% of the aging population above 65 years old suffer from HF.

    The outcomes of HF are very poor: 5 year mortality rate is higher than 60% – worse than many types of cancer. There are 1 million hospitalizations per year due to HF in the US. HF accounts from more hospitalization-days than any other disease. HF is the number 1 cause for readmission within 30 days – higher than 20% re-admission rates. The current annual cost of HF to the US economy is a huge $31B, with annual cost projected to reach $70B by 2030.

    Figure 1 shows the poor outcomes of patient hospitalizations due to heart failure, as reflected by high mortality rates at 30 days, 12 months, and 5 years, and high rate of hospital readmissions. Figure 2 shows the poor and deteriorating median survival time after every HF hospitalization. Kidney failure accounts for more than 50% of mortality, as the kidneys heavily depend on sufficient blood pressure, and blood flow for their operation, which is obviously affected by HF.
    http://seekingalpha.com/article/3811136-sunshine-heart-a-speculative-biotech-play-for-substantial-short-term-gains?auth_param=17tckm:1b9fvn8:1e097e95787e20c025e6c8de8e008836&dr=1

Featured Stories

Macron Bypasses Parliament With ‘Nuclear Option’ on Retirement Age Hike

Angry Bear

All Electric comes to Heavy Equipment

Daniel Becker

Medicare Plan Commissions May Steer Beneficiaries to Wrong Coverage

run75441

Thoughts on Silicon Valley Bank: Why the FDIC plan isn’t (but also is) a Bailout

NewDealdemocrat

Contributors

Dan Crawford
Robert Waldmann
Barkley Rosser
Eric Kramer
ProGrowth Liberal
Daniel Becker
Ken Houghton
Linda Beale
Mike Kimel
Steve Roth
Michael Smith
Bill Haskell
NewDealdemocrat
Ken Melvin
Sandwichman
Peter Dorman
Kenneth Thomas
Bruce Webb
Rebecca Wilder
Spencer England
Beverly Mann
Joel Eissenberg

Subscribe

Blogs of note

    • Naked Capitalism
    • Atrios (Eschaton)
    • Crooks and Liars
    • Wash. Monthly
    • CEPR
    • Econospeak
    • EPI
    • Hullabaloo
    • Talking Points
    • Calculated Risk
    • Infidel753
    • ACA Signups
    • The one-handed economist
Angry Bear
Copyright © 2023 Angry Bear Blog

Topics

  • US/Global Economics
  • Taxes/regulation
  • Healthcare
  • Law
  • Politics
  • Climate Change
  • Social Security
  • Hot Topics
  • US/Global Economics
  • Taxes/regulation
  • Healthcare
  • Law
  • Politics
  • Climate Change
  • Social Security
  • Hot Topics

Pages

  • About
  • Contact
  • Editorial
  • Policies
  • Archives